instruction stringlengths 44 150 | context stringlengths 55 176 | response stringlengths 40 109 |
|---|---|---|
Does the dossier include a maintenance plan for manufacturing equipment? | The dossier states: 'All equipment undergoes routine maintenance as per SOP EQ-1234.' | Compliant. A maintenance plan for manufacturing equipment is included. |
Check if the dossier provides a detailed description of excipient functions. | The dossier specifies: 'Lactose acts as a filler, and magnesium stearate as a lubricant.' | Compliant. The functions of excipients are described. |
Verify if the dossier includes data on endotoxin testing for water used in manufacturing. | The dossier includes endotoxin testing results: 'Endotoxin levels <0.25 EU/mL.' | Compliant. Endotoxin testing data is included. |
Does the dossier describe the procedures for cleaning manufacturing facilities? | The dossier specifies: 'Daily cleaning procedures are documented under SOP CLN-001.' | Compliant. Cleaning procedures for manufacturing facilities are described. |
Check if the dossier includes details on the qualification of manufacturing equipment. | The dossier includes qualification data for blenders and sterilizers but lacks data for filling machines. | Gap. Qualification data for filling machines is missing. |
Verify if the dossier includes specifications for novel excipients. | The dossier specifies: 'Novel excipient XYZ has a purity specification of NLT 98.0%.' | Compliant. Specifications for novel excipients are included. |
Does the dossier include a list of materials used in primary packaging? | The dossier specifies: 'Primary packaging includes Type I glass vials and aluminum seals.' | Compliant. Materials used in primary packaging are listed. |
Check if the dossier includes microbial limit testing data for excipients. | The dossier provides microbial limit testing results for lactose and magnesium stearate. | Compliant. Microbial limit testing data for excipients is included. |
Verify if the dossier specifies the manufacturing site's contingency plan for power failures. | The dossier states: 'Backup generators are tested monthly to ensure uninterrupted operations during power failures.' | Compliant. A contingency plan for power failures is specified. |
Does the dossier provide details on the audit history of raw material suppliers? | The dossier lacks audit history records for the supplier of lactose. | Gap. Audit history records for the supplier of lactose are missing. |
Check if the dossier includes details on the stability-indicating analytical method. | The dossier specifies: 'HPLC is used as a stability-indicating analytical method and is fully validated.' | Compliant. Stability-indicating analytical method details are included. |
Verify if the dossier includes a list of potential cross-contaminants in shared facilities. | The dossier lacks a list of potential cross-contaminants in shared facilities. | Gap. A list of potential cross-contaminants is missing. |
Does the dossier describe the shelf-life extension plan for the drug product? | The dossier specifies: 'Shelf-life extension studies will be conducted after 12 months of initial stability testing.' | Compliant. A shelf-life extension plan is described. |
Check if the dossier provides a summary of storage conditions for raw materials. | The dossier specifies: 'Raw materials must be stored at 15-25°C in a dry environment.' | Compliant. Storage conditions for raw materials are summarized. |
Verify if the dossier includes a list of critical material attributes (CMAs). | The dossier specifies: 'Critical material attributes include particle size and polymorphism of the API.' | Compliant. A list of critical material attributes is included. |
Does the dossier include data on leachables from primary packaging? | The dossier lacks data on leachables from rubber stoppers. | Gap. Data on leachables from rubber stoppers is missing. |
Check if the dossier includes a list of all testing laboratories used for analysis. | The dossier specifies: 'Testing is conducted at ABC Analytical Lab and XYZ Quality Services.' | Compliant. A list of testing laboratories is included. |
Verify if the dossier specifies the manufacturing site's water treatment process. | The dossier specifies: 'Water is treated using reverse osmosis followed by UV sterilization.' | Compliant. The manufacturing site's water treatment process is specified. |
Does the dossier include risk mitigation strategies for environmental contaminants? | The dossier specifies: 'Air quality is monitored daily to mitigate risks of microbial contamination.' | Compliant. Risk mitigation strategies for environmental contaminants are included. |
Check if the dossier provides evidence of compliance with regional pharmacopoeial standards. | The dossier states: 'API complies with USP, Ph. Eur., and JP standards.' | Compliant. Evidence of compliance with regional pharmacopoeial standards is provided. |
Verify if the dossier includes a description of the manufacturing facility. | The dossier specifies: 'Manufacturing site located at XYZ, equipped with Class 100 cleanrooms.' | Compliant. The dossier includes a detailed description of the manufacturing facility. |
Check if facility validation data is provided. | Validation data for HVAC systems is not included in the dossier. | Gap. Validation data for HVAC systems is missing. |
Does the dossier describe the facility's quality control laboratory? | The dossier includes: 'The QC lab is equipped with validated HPLC and GC systems.' | Compliant. The dossier provides details of the QC laboratory. |
Is the equipment used in manufacturing listed in the dossier? | The dossier includes a list of equipment, but calibration records are missing. | Gap. Equipment list is provided, but calibration records are not included. |
Does the dossier include a safety evaluation for adventitious agents? | The dossier includes data on viral clearance but lacks bacterial endotoxin testing. | Gap. Bacterial endotoxin testing is missing from the safety evaluation. |
Check if TSE/BSE risks are addressed in the dossier. | The dossier states: 'All excipients are derived from non-animal sources.' | Compliant. TSE/BSE risks are addressed adequately. |
Does the dossier include validation studies for viral clearance? | The dossier includes viral clearance validation studies for the API. | Compliant. Viral clearance validation is included. |
Verify if excipients comply with compendial standards. | Excipients listed include lactose (Ph. Eur.) and magnesium stearate (USP). | Compliant. Excipients comply with compendial standards. |
Check if toxicity data for novel excipients is included. | The dossier lacks toxicity data for novel excipient XYZ. | Gap. Toxicity data for novel excipient XYZ is missing. |
Does the dossier include justification for excipient selection? | The dossier provides compatibility studies between API and excipients. | Compliant. Justification for excipient selection is included. |
Does the dossier include stability data for Zone IVb conditions? | The dossier includes stability data for 30°C/75% RH conditions. | Compliant. Stability data for Zone IVb conditions is provided. |
Check if country-specific regulatory certificates are included. | The dossier includes a valid CEP for the active pharmaceutical ingredient. | Compliant. The dossier includes country-specific regulatory certificates. |
Does the dossier address region-specific labeling requirements? | The dossier provides labels meeting EMA and FDA guidelines, but PMDA requirements are not addressed. | Gap. PMDA-specific labeling requirements are missing. |
Verify if the dossier lists all manufacturing sites. | The dossier includes a list of manufacturing sites with complete addresses. | Compliant. All manufacturing sites are listed in the dossier. |
Does the dossier include a cleaning validation report for manufacturing equipment? | The dossier lacks a cleaning validation report for critical manufacturing equipment. | Gap. Cleaning validation report is missing. |
Check if the dossier includes an impurity profile for the API. | The dossier includes impurity profiles for Impurity A and Impurity B but lacks data for Impurity C. | Gap. Impurity profile for Impurity C is missing. |
Is analytical method validation included in the dossier? | Validation for HPLC methods is provided in the dossier. | Compliant. Analytical method validation is included. |
Does the dossier include a description of the container closure system? | The dossier specifies: 'The drug product is stored in Type I glass vials with rubber stoppers.' | Compliant. The container closure system is described in detail. |
Does the dossier include a risk assessment for adventitious agents? | The dossier lacks a detailed risk assessment for adventitious agents. | Gap. A risk assessment for adventitious agents is missing. |
Verify if storage conditions are specified in the dossier. | The dossier specifies: 'Store below 25°C and protect from light.' | Compliant. Storage conditions are clearly stated. |
Check if the dossier includes details of water quality used in manufacturing. | The dossier specifies: 'Water for Injection (WFI) is used in all manufacturing steps and complies with Ph. Eur. standards.' | Compliant. The dossier includes details of water quality and compliance with Ph. Eur. standards. |
Verify if process validation data for critical manufacturing steps is included. | The dossier provides process validation data for blending and granulation, but lacks data for sterilization. | Gap. Process validation data for sterilization is missing. |
Does the dossier include details of the primary packaging material? | The dossier describes the primary packaging as 'Type I glass vials with Teflon-coated stoppers.' | Compliant. Primary packaging materials are described in detail. |
Check if stability testing conditions align with ICH guidelines. | The stability testing conditions are reported as 25°C/60% RH and 40°C/75% RH. | Compliant. Stability testing conditions align with ICH Q1A guidelines. |
Does the dossier include impurity control limits for the API? | The dossier specifies: 'Impurity A: NMT 0.5%, Impurity B: NMT 0.2%.' | Compliant. Impurity control limits for the API are included. |
Verify if the dossier includes a justification for the choice of manufacturing process. | The dossier states: 'Wet granulation was selected based on API solubility and stability studies.' | Compliant. The dossier includes a justification for the manufacturing process. |
Does the dossier include a description of reconstitution instructions for the drug product? | The dossier provides detailed instructions: 'Reconstitute with 10 mL of sterile water and shake gently until dissolved.' | Compliant. Reconstitution instructions are provided in detail. |
Check if the dossier includes a risk assessment for nitrosamine impurities. | The dossier includes a nitrosamine risk assessment and concludes no significant risk of contamination. | Compliant. The dossier includes a nitrosamine risk assessment. |
Does the dossier provide stability data for photostability testing? | Photostability testing data is not included in the dossier. | Gap. Photostability testing data is missing. |
Verify if batch release testing results are included in the dossier. | The dossier includes batch release testing results for three validation batches. | Compliant. Batch release testing results are included. |
Check if the dossier includes microbial limit testing results. | Microbial limit testing results are provided for three production batches. | Compliant. Microbial limit testing results are included. |
Does the dossier specify overages in the drug product composition? | The dossier states: 'A 2% overage of the active ingredient is included to compensate for degradation during shelf life.' | Compliant. Overages are specified and justified. |
Verify if residual solvent testing results are included. | The dossier includes residual solvent testing results and confirms compliance with ICH Q3C limits. | Compliant. Residual solvent testing results are included. |
Does the dossier provide a summary of elemental impurity testing? | The dossier states: 'Elemental impurities are below the ICH Q3D specified limits.' | Compliant. A summary of elemental impurity testing is provided. |
Check if the dossier includes evidence of GMP certification for all manufacturing sites. | The dossier includes GMP certificates for all manufacturing sites involved in production. | Compliant. GMP certification is provided for all manufacturing sites. |
Does the dossier include characterization data for the API? | The dossier includes data on API polymorphism, particle size distribution, and solubility. | Compliant. API characterization data is included. |
Verify if the dossier includes justification for container closure integrity testing. | The dossier provides: 'Container closure integrity was tested using dye ingress and microbial challenge tests.' | Compliant. Justification for container closure integrity testing is included. |
Does the dossier include validation data for cleaning processes? | The dossier provides cleaning validation data for all equipment used in production. | Compliant. Cleaning validation data is included. |
Check if the dossier specifies storage conditions during transportation. | The dossier states: 'Transport under controlled conditions of 2-8°C in validated containers.' | Compliant. Storage conditions during transportation are specified. |
Verify if the dossier includes validation studies for the sterilization process. | The dossier lacks validation studies for the sterilization process. | Gap. Validation studies for the sterilization process are missing. |
Verify if the dossier includes a detailed flowchart of the manufacturing process. | The dossier provides a flowchart showing all major steps, including granulation, drying, and packaging. | Compliant. The manufacturing process flowchart is included. |
Check if the dossier includes information on critical process parameters (CPPs). | Critical process parameters for mixing time and temperature are documented. | Compliant. Critical process parameters are provided in the dossier. |
Does the dossier include a risk assessment for cross-contamination in shared facilities? | The dossier lacks a risk assessment for cross-contamination in shared facilities. | Gap. A risk assessment for cross-contamination is missing. |
Verify if the dossier includes data on container closure leachables and extractables. | The dossier includes data for extractables but lacks testing results for leachables. | Gap. Leachables testing data is missing. |
Check if the dossier includes the target product profile (TPP). | The dossier includes a TPP describing intended use, dosage, and shelf life. | Compliant. The target product profile is included. |
Does the dossier provide environmental monitoring data for the manufacturing facility? | Environmental monitoring data for air quality and microbial load is provided. | Compliant. Environmental monitoring data is included. |
Verify if the dossier includes a description of the reprocessing strategy. | The dossier lacks a clear strategy for reprocessing non-conforming batches. | Gap. A reprocessing strategy is missing. |
Check if the dossier includes cleaning agent residue limits. | Residue limits for cleaning agents are defined and validated. | Compliant. Cleaning agent residue limits are included. |
Does the dossier provide a summary of water system validation? | The dossier includes a summary of water system validation for WFI generation. | Compliant. Water system validation summary is included. |
Verify if the dossier includes microbial challenge studies for the container closure system. | The dossier lacks microbial challenge study results for the container closure system. | Gap. Microbial challenge study results are missing. |
Check if the dossier includes a justification for the selected packaging material. | The dossier states: 'Type I glass vials were selected due to their inert nature and compatibility with the formulation.' | Compliant. Justification for packaging material selection is included. |
Does the dossier include data on the sterility testing method? | The sterility testing method is validated and included in the dossier. | Compliant. Sterility testing method data is included. |
Verify if the dossier specifies the overfill volume for the drug product. | The dossier lacks information on the overfill volume for the drug product. | Gap. Overfill volume information is missing. |
Check if the dossier includes evidence of employee training in GMP compliance. | The dossier includes training logs and certificates for GMP compliance. | Compliant. Employee GMP training records are included. |
Does the dossier include compatibility data for the API and excipients? | Compatibility studies between the API and excipients are included in the dossier. | Compliant. Compatibility data is included. |
Verify if the dossier includes a summary of deviations during manufacturing. | The dossier includes a deviation summary for three production batches. | Compliant. Summary of deviations is included. |
Check if the dossier includes stability data for reconstituted drug products. | Stability data for the reconstituted solution is not included in the dossier. | Gap. Stability data for reconstituted drug products is missing. |
Does the dossier provide a justification for the choice of shelf life? | The dossier justifies a 24-month shelf life based on long-term stability data. | Compliant. Shelf life justification is included. |
Verify if the dossier includes a list of potential impurities in excipients. | The dossier lists potential impurities for magnesium stearate and lactose. | Compliant. Potential impurities in excipients are listed. |
Check if the dossier specifies sterilization methods for primary packaging. | Sterilization methods for rubber stoppers and glass vials are included. | Compliant. Sterilization methods for primary packaging are specified. |
Does the dossier include a description of the manufacturing process that complies with ICH Q7? | The dossier states: 'The drug is manufactured using a closed-system process, with each step detailed in the process flowchart.' | Compliant. The manufacturing process is described in line with ICH Q7. |
Check if the dossier provides evidence of equipment validation as per ICH Q7. | The dossier includes: 'All manufacturing equipment is validated according to SOP EQ-2345, ensuring accuracy and precision.' | Compliant. Equipment validation is documented according to ICH Q7. |
Does the dossier provide stability testing data for the drug product as per ICH Q1? | The dossier includes: 'Stability studies at accelerated and real-time conditions have been conducted, supporting a 24-month shelf life.' | Compliant. Stability data for the drug product is provided in accordance with ICH Q1. |
Has the dossier included a risk assessment for microbial contamination during production, following ICH Q9? | The dossier specifies: 'Risk assessments for microbial contamination were conducted and corrective actions were implemented.' | Compliant. A risk assessment for microbial contamination is included. |
Check if the dossier includes the required toxicity data for novel excipients as per ICH Q3D. | The dossier includes: 'Toxicity studies for excipients such as sorbitol and mannitol were conducted according to ICH Q3D guidelines.' | Compliant. Toxicity data for excipients is provided as per ICH Q3D. |
Does the dossier outline the cleaning procedures for manufacturing equipment, as required by ICH Q7? | The dossier states: 'Cleaning is done after each production run, with cleaning agents specified in SOP EQ-1234.' | Compliant. Cleaning procedures for equipment are described in accordance with ICH Q7. |
Check if the dossier demonstrates control of impurities in excipients according to ICH Q3D. | The dossier includes: 'Excipient purity is tested regularly, with limits set according to ICH Q3D standards.' | Compliant. Impurity control for excipients is in place according to ICH Q3D. |
Has the dossier provided a validation for the analytical methods used for drug testing in compliance with ICH Q2? | The dossier includes: 'Analytical methods for testing purity and potency have been validated for accuracy and precision.' | Compliant. Validation of analytical methods is provided as per ICH Q2. |
Does the dossier specify the conditions for storage and transportation of the drug product, in line with ICH Q1? | The dossier specifies: 'The drug product should be stored at 25°C ± 2°C and protected from light.' | Compliant. Storage and transportation conditions are specified as per ICH Q1. |
Check if the dossier provides an appropriate shelf life for the drug product, following ICH Q1B photostability testing guidelines. | The dossier includes: 'Photostability testing has been performed to ensure stability under light exposure, with no significant degradation observed.' | Compliant. Shelf life is supported by photostability testing as per ICH Q1B. |
Does the dossier provide evidence that excipients used in the drug product meet ICH Q6A standards? | The dossier includes: 'Excipients have been tested for identity, purity, and quality to meet ICH Q6A standards.' | Compliant. Excipients meet ICH Q6A quality standards. |
Check if the dossier includes a detailed description of the batch release process as required by ICH Q7. | The dossier states: 'Batch release is done after all tests are passed, including potency and purity assessments.' | Compliant. The batch release process is detailed as per ICH Q7. |
Does the dossier include microbial testing results for the drug product as required by ICH Q6A? | The dossier specifies: 'Microbial testing results are included, showing no microbial contamination in the drug product.' | Compliant. Microbial testing results are provided as per ICH Q6A. |
Check if the dossier demonstrates that the drug substance complies with ICH Q6A specifications for impurities. | The dossier includes: 'The drug substance meets impurity limits as outlined in ICH Q6A, with no detected impurities exceeding 0.1%.' | Compliant. The drug substance meets impurity specifications according to ICH Q6A. |
Does the dossier include stability data for both drug substance and drug product in accordance with ICH Q1? | The dossier includes: 'Stability data for both drug substance and product have been provided, showing stability over 36 months under specified conditions.' | Compliant. Stability data for both drug substance and drug product is included according to ICH Q1. |
Has the dossier provided adequate endotoxin testing results for injectable products as required by ICH Q7? | The dossier specifies: 'Endotoxin levels were measured and found to be below the ICH Q7 acceptable limits for injectable products.' | Compliant. Endotoxin testing for injectable products is included and meets ICH Q7 limits. |
Check if the dossier includes proper environmental monitoring data to demonstrate compliance with ICH Q7. | The dossier includes: 'Environmental monitoring records for temperature, humidity, and microbial levels during production are included.' | Compliant. Environmental monitoring data is provided in accordance with ICH Q7. |
Does the dossier include a detailed procedure for batch-to-batch consistency testing as required by ICH Q7? | The dossier specifies: 'Batch-to-batch consistency is tested for all critical parameters, including potency and purity.' | Compliant. Batch-to-batch consistency is tested and documented according to ICH Q7. |
Check if the dossier includes data on the characterization of new excipients used in the formulation, as per ICH Q6A. | The dossier includes: 'New excipients have been characterized for identity, purity, and other quality attributes, in accordance with ICH Q6A.' | Compliant. New excipients are characterized per ICH Q6A guidelines. |
Has the dossier demonstrated that the drug product complies with ICH Q1B stability guidelines for temperature sensitivity? | The dossier specifies: 'Stability testing for temperature sensitivity has been performed, confirming the product remains stable at 2°C - 8°C for 12 months.' | Compliant. Temperature sensitivity testing meets ICH Q1B requirements. |
End of preview. Expand in Data Studio
README.md exists but content is empty.
- Downloads last month
- 11